Eintrag weiter verarbeiten
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 106(2012), 6, Seite 1239-1245 |
|---|---|
| Personen und Körperschaften: | , , |
| Titel: | Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial/ A. Tikidzhieva, A. Benner, S. Michel, A. Formentini, K.-H. Link, W. Dippold, M. von Knebel Doeberitz, M. Kornmann and M. Kloor |
| Format: | E-Book-Kapitel |
| Sprache: | Englisch |
| veröffentlicht: |
21 February 2012
|
| Gesamtaufnahme: |
: British journal of cancer, 106(2012), 6, Seite 1239-1245
, volume:106 |
| Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
| Zusammenfassung: | Background: High-level microsatellite instability (MSI-H) has been reported as a prognostic marker in colon cancer. We here analysed the prognostic significance of MSI and mutations of the Beta2-Microglobulin (B2M) gene, which occur in about 30% of MSI-H colon cancer, in the cohort of the prospective FOGT-4 (Forschungsruppe Onkologie Gastrointestinale Tumoren, FOGT) trial. Methods: Microsatellite instability status was determined using standard protocols (NCI/ICG-HNPCC panel and CAT25) in 223 colon cancer lesions. Beta2-Microglobulin mutation status was evaluated by exon-wise sequencing in all MSI-H lesions. Results: Patients with MSI-H (n=34) colon cancer presented with a significantly lower risk of relapse after 12 months of follow-up compared with MSS (n=189) colon cancer patients (5 year time to relapse: MSI-H 0.82 vs MSS 0.66, P=0.03). No significant difference in overall survival was detected. Beta2-Microglobulin mutations were identified in 10 (29.4%) out of 34 MSI-H colon cancers and were associated with a complete absence of disease relapse or tumour-related death events (P=0.09). Conclusion: The risk of late disease relapse was significantly lower in patients with MSI-H compared with MSS colon cancer. Moreover, B2M mutations may contribute to the favourable outcome of MSI-H colon cancer patients and should therefore be evaluated as a potential prognostic marker in future clinical trials. |
|---|---|
| Beschreibung: | Gesehen am 30.05.2018 |
| Umfang: | 7 |
| ISSN: |
1532-1827
|
| DOI: | 10.1038/bjc.2012.53 |